Command Palette

Search for a command to run...

Clinical Trials · NCT05897372

Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot Study

TerminatedPhase 2Semaglutide (Prohibited)
Phase
Phase 2
Recruitment status
Terminated
Sponsor
Iain Bressendorff
Enrollment
1
Start date
Aug 2023
Locations
1 site, Denmark
Primary endpoint
urine albumin/creatinin-ratio (UACR) reduction to less than 50% of baseline
View Semaglutide compound reference